Wyeth Librel NDA Accepted By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth expects a standard 10-month review for its continuous-use contraceptive; the NDA for the low-dose levonorgestrel/ethinyl estradiol product was submitted May 27